BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26177208)

  • 1. Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2.
    Park SH; Park S; Kim DY; Pyo A; Kimura RH; Sathirachinda A; Choy HE; Min JJ; Gambhir SS; Hong Y
    PLoS One; 2015; 10(7):e0132976. PubMed ID: 26177208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of monobody conjugates for human EphA2-specific optical imaging.
    Kim MA; Yoon HS; Park SH; Kim DY; Pyo A; Kim HS; Min JJ; Hong Y
    PLoS One; 2017; 12(7):e0180786. PubMed ID: 28686661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering of an EPHA2-Targeted Monobody for the Detection of Colorectal Cancer.
    Venu A; Zhang Y; Seong J; Hong Y; Lee WS; Min JJ
    Cancer Genomics Proteomics; 2024; 21(3):285-294. PubMed ID: 38670584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of
    Pyo A; You SH; Sik Kim H; Young Kim J; Min JJ; Kim DY; Hong Y
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127262. PubMed ID: 32527560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies.
    Lipovsek D; Lippow SM; Hackel BJ; Gregson MW; Cheng P; Kapila A; Wittrup KD
    J Mol Biol; 2007 May; 368(4):1024-41. PubMed ID: 17382960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.
    Ullman C; Mathonet P; Oleksy A; Diamandakis A; Tomei L; Demartis A; Nardi C; Sambucini S; Missineo A; Alt K; Hagemeyer CE; Harris M; Hedt A; Weis R; Gehlsen KR
    PLoS One; 2015; 10(8):e0135278. PubMed ID: 26313909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directed Evolution of a Highly Specific FN3 Monobody to the SH3 Domain of Human Lyn Tyrosine Kinase.
    Huang R; Fang P; Hao Z; Kay BK
    PLoS One; 2016; 11(1):e0145872. PubMed ID: 26731115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibronectin type III domain based monobody with high avidity.
    Duan J; Wu J; Valencia CA; Liu R
    Biochemistry; 2007 Nov; 46(44):12656-64. PubMed ID: 17929945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold.
    Koide A; Wojcik J; Gilbreth RN; Hoey RJ; Koide S
    J Mol Biol; 2012 Jan; 415(2):393-405. PubMed ID: 22198408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain.
    Koide A; Koide S
    Methods Mol Biol; 2007; 352():95-109. PubMed ID: 17041261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational and biophysical robustness in a prestabilized monobody.
    Chandler PG; Tan LL; Porebski BT; Green JS; Riley BT; Broendum SS; Hoke DE; Falconer RJ; Munro TP; Buckle M; Jackson CJ; Buckle AM
    J Biol Chem; 2021; 296():100447. PubMed ID: 33617878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
    Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
    Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein.
    Matsui H; Sakurai F; Katayama K; Abe Y; Machitani M; Kurachi S; Tachibana M; Mizuguchi H
    Biomaterials; 2013 May; 34(16):4191-4201. PubMed ID: 23473963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
    Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain.
    Chandler PG; Buckle AM
    Cells; 2020 Mar; 9(3):. PubMed ID: 32143310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin.
    Gebauer M; Schiefner A; Matschiner G; Skerra A
    J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-affinity single-domain binding proteins with a binary-code interface.
    Koide A; Gilbreth RN; Esaki K; Tereshko V; Koide S
    Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6632-7. PubMed ID: 17420456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo.
    Lee CH; Park KJ; Sung ES; Kim A; Choi JD; Kim JS; Kim SH; Kwon MH; Kim YS
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9567-71. PubMed ID: 20460308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EDB Fibronectin Specific Peptide for Prostate Cancer Targeting.
    Han Z; Zhou Z; Shi X; Wang J; Wu X; Sun D; Chen Y; Zhu H; Magi-Galluzzi C; Lu ZR
    Bioconjug Chem; 2015 May; 26(5):830-8. PubMed ID: 25848940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FN3: a new protein scaffold reaches the clinic.
    Bloom L; Calabro V
    Drug Discov Today; 2009 Oct; 14(19-20):949-55. PubMed ID: 19576999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.